YOU ARE HERE: LAT HomeCollections


No magic bullet on the flu

Digging into reports on Tamiflu's effectiveness yielded some surprises — and a $200 settlement.

January 15, 2012|By David Finkelstein
(AP Photo/Nati Harnik )

In recent weeks I've had occasion to wonder whether Talmudic scholars of yore ever debated the question of what to do when a nice Jewish boy came down with swine flu. Less shameful than a diagnosis of trichinosis, perhaps, in which the subject would surely be harshly judged for his complicity in having partaken of undercooked pork. Yet hasn't a swine flu victim also ingested (or at least inhaled) the virus one way or another?

Admittedly, this was not foremost on my mind when, in 2006, my wife and I purchased a drug called Tamiflu. It was at a time, you may recall, when every allegedly responsible health agency — including the Centers for Disease Control and Prevention in Atlanta and the World Health Organization in Geneva — warned of the imminent onset of an avian flu "pandemic" of lethal proportions, comparable to the Spanish flu of 1918, which claimed up to 100 million lives.

My wife and I were soon to be leaving on a writing assignment abroad, and Tamiflu was being touted as effective in reducing the "secondary complications" of flu, including bronchitis and pneumonia. As it turned out, however, trying to buy two courses of Tamiflu proved difficult. The pandemic scare had prompted a rash of panic buying, and nary a pill was to be found. As revealed later, President George W. Bush, ever solicitous of the nation's health — primarily the health of all those young men and women he had sent off to Iraq and Afghanistan — had spent more than $1 billion of taxpayers' money to stockpile the drug. We finally managed to get the pills through a mail-order pharmacy in Canada.

Not surprisingly, we never did come down with avian flu; hardly anyone did. The pandemic never occurred.

Fast-forward to 2011, when a random inventory of our medicine chest revealed the unused Tamiflu pills hidden behind a box of Band-Aids. Maybe we should have discarded them earlier, but our decision to keep them was no doubt influenced by a media campaign in 2009 that proclaimed the threat of yet another frightening outbreak. This time it was swine flu, and — surprise, surprise — Tamiflu was again touted as the drug to save the day.

So you can imagine our surprise when just a few months ago, while browsing through an article titled "Reckless Medicine" in the magazine Discover, we came upon an astounding story. After reviewing studies of Tamiflu during the avian flu scare, Dr. Tom Jefferson of the Cochrane Collaboration, a nonprofit group dedicated to analyzing medical evidence, had concluded in a 2006 report that the drug was effective. "But," said the article, "several years later, another physician challenged that conclusion because 8 of 10 studies in a meta-analysis — a review of studies — that Jefferson relied on had never been published."

That prompted Jefferson to seek the raw data. "He was stymied when several authors and the manufacturer gave one excuse after another for why it couldn't supply the actual data. Jefferson's concern turned to outrage when two employees of a communications company … [revealed] they had been paid to ghostwrite some of the Tamiflu studies [and] had been given explicit instructions to ensure that a key message was embedded in the articles: Flu is a threat, and Tamiflu is the answer.

"After reanalyzing the raw data finally made available (they still don't have it all), Jefferson and his colleagues published their review [in December 2009], saying that once the unpublished studies were excluded, there was no proof that Tamiflu reduced serious flu complications like pneumonia or death."

In short, it appears the pharmaceutical companies had been as cunning in conning the public on matters of health as Wall Street had been on matters of wealth.

After reading this article and doing a morning's online research, we phoned Genentech Corp., a U.S. affiliate of Hoffmann-La Roche, the Swiss drug giant that holds marketing rights to Tamiflu. Our aim was simply to get the company's response to the allegations. But the customer service representative adamantly refused to discuss the issue, in essence telling us to get lost but to have a nice day.

Stonewalled, we wrote directly to Genentech's chief, Ian Clark, suggesting that because it appeared we'd been misled into purchasing Tamiflu, the simplest solution would be a return of the pills for a refund of the $120 we had paid for them. But unlike his underling, who at least had wished us a nice day, Clark didn't even bother to respond. And so, much as we two senior citizens from New York shrank at the thought of an early-morning PATH trip to Newark, N.J., we bit the bullet and filed a small-claims action in a New Jersey court, that jurisdiction being the closest location where Genentech was licensed to do business. Our suit alleged breach of contract by way of fraud.

Los Angeles Times Articles